MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • Galena Biopharma, Inc. (GALE) Presses Toward Corporate Goals With Support From Seasoned Professionals 0 comments
    Dec 18, 2013 5:29 PM | about stocks: GALE

    Galena Biopharma is a developer of targeted oncology treatments designed to address major unmet medical needs to advance cancer care. The company is making significant progress in the advancement of candidates in its portfolio, guided by a management team comprised of experienced biotech management and scientists with a vision to accelerate value for both patients and shareholders.

    Mark J. Ahn, Ph.D., backed with more than 20 years of experience in the biopharmaceutical industry, has served as Galena's president and CEO since March 31, 2011, and as a director since 2007. He is also an adjunct professor of biosciences at Creighton University. Dr. Ahn previously was a principal at Pukana Partners, Ltd., which provides strategic consulting to life science companies; and associate professor of global management at Atkinson Graduate School of Management, Willamette University. Among other achievements, Dr. Ahn was also founder and CEO of Hana Biosciences; vice president of hematology and corporate officer at Genentech, Inc.; and held positions of increasing responsibility at Amgen and Bristol-Myers Squibb. Aside from serving on several boards of directors, Dr. Ahn has authored more than 50 peer reviewed journal articles and books. He is educated with a B.A. and M.B.A. from Chaminade University; an M.A. from Victoria University; was a graduate fellow in Economics at Essex University; and obtained a Ph.D. from the University of South Australia.

    Galena's executive vice president and Chief Medical Officer Dr. Brian Hamilton, M.D., Ph.D has extensive academic and pharmaceutical experience in immunology, hematopoietic stem cell transplantation, and oncology. Through his tenure with pharmaceutical and biotech companies, Dr. Hamilton's experience includes drug development across multiple therapeutic indications and platforms, including small molecules, biologics, oncolytic viruses, and vaccines. Dr. Hamilton received his M.D. and Ph.D. from the University of Washington School of Medicine with extensive specialty training to include pediatrics at the Children's Medical Center in Dallas, Texas; immunology at the Children's Hospital Medical Center and Sidney Farber Cancer Center; and allergy at the University of California-San Francisco. He has held academic appointments at the University of Washington and the University of Miami.

    Prior to his current role as Galena's executive vice president and chief operating officer, Dr. Mark W. Schwartz served as executive vice president and COO of RXi Pharmaceuticals; president and CEO of Bayhill Therapeutics, a company developing a DNA vaccine platform for the treatment of autoimmune diseases where he completed a successful partnership with Genentech for the development of the company's type 1 diabetes vaccine; and president and CEO of Calyx Therapeutics, which doubled its size and completed key phase I and phase II international clinical trials of novel anti-inflammatory compounds during his tenure.

    The doctors are supported by a management team of highly qualified individuals as well as scientific and advisory boards.

    For more information, visit galenabiopharma.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: GALE
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.